E.Campo NLH, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO classification of tumors of haematopoietic and lymphoid tissues. (IARC Press; 2016).

O’Donnell EK, Shapiro YN, Yee AJ, Nadeem O, Hu BY, Laubach JP, et al. Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. Cancer 2022;128:1996–2004.

Article  PubMed  Google Scholar 

Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia 2020;34:1–20.

Article  PubMed  Google Scholar 

Dima D, Ullah F, Mazzoni S, Williams L, Faiman B, Kurkowski A, et al. Management of relapsed-refractory multiple myeloma in the era of advanced therapies: evidence-based recommendations for routine clinical practice. Cancers. 2023;15:2160.

Pintoffl JP, Weisel K, Schulze M, Maksimovic O, Claussen CD, Kramer U, et al. Role of dynamic contrast-enhanced sonography for characterization and monitoring of extramedullary myeloma: comparison with serologic data. J Ultrasound Med 2013;32:1777–88.

Article  PubMed  Google Scholar 

Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 2017;18:e206–e17.

Article  PubMed  Google Scholar 

Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R, et al. Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. Haematologica 2020;105:193–200.

Article  PubMed  PubMed Central  Google Scholar 

Blade J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J 2022;12:45.

Article  PubMed  PubMed Central  Google Scholar 

Rosinol L, Beksac M, Zamagni E, Van de Donk N, Anderson KC, Badros A, et al. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol 2021;194:496–507.

Article  PubMed  Google Scholar 

Terpos E, Rezvani K, Basu S, Milne AE, Rose PE, Scott GL, et al. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur J Haematol 2005;75:376–83.

Article  PubMed  Google Scholar 

Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica 2012;97:1761–7.

Article  PubMed  PubMed Central  Google Scholar 

Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 2011;25:906–8.

Article  PubMed  PubMed Central  Google Scholar 

Wu P, Davies FE, Boyd K, Thomas K, Dines S, Saso RM, et al. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma 2009;50:230–5.

Article  PubMed  Google Scholar 

Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2010;21:325–30.

Article  PubMed  Google Scholar 

Deng H, Liu M, Yuan T, Zhang H, Cui R, Li J, et al. Efficacy of humanized Anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma patients with and without extramedullary disease. Front Immunol 2021;12:720571.

Article  PubMed  PubMed Central  Google Scholar 

Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005;105:317–23.

Article  PubMed  Google Scholar 

de Haart SJ, Willems SM, Mutis T, Koudijs MJ, van Blokland MT, Lokhorst HM, et al. Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses. Blood Cancer J 2016;6:e426.

Article  PubMed  PubMed Central  Google Scholar 

Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov 2013;3:862–9.

Article  PubMed  Google Scholar 

Liu Y, Jelloul F, Zhang Y, Bhavsar T, Ho C, Rao M, et al. Genetic basis of extramedullary plasmablastic transformation of multiple myeloma. Am J Surg Pathol 2020;44:838–48.

Article  PubMed  PubMed Central  Google Scholar 

Kortum KM, Mai EK, Hanafiah NH, Shi CX, Zhu YX, Bruins L, et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood 2016;128:1226–33.

Article  PubMed  PubMed Central  Google Scholar 

Chang H, Sloan S, Li D, Keith Stewart A. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol 2004;127:280–4.

Article  PubMed  Google Scholar 

Qu X, Chen L, Qiu H, Lu H, Wu H, Qiu H, et al. Extramedullary manifestation in multiple myeloma bears high incidence of poor cytogenetic aberration and novel agents resistance. Biomed Res Int 2015;2015:787809.

Article  PubMed  PubMed Central  Google Scholar 

Billecke L, Murga Penas EM, May AM, Engelhardt M, Nagler A, Leiba M, et al. Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol 2013;161:87–94.

Article  PubMed  Google Scholar 

Maura F, Bolli N, Angelopoulos N, Dawson KJ, Leongamornlert D, Martincorena I, et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun 2019;10:3835.

Article  PubMed  PubMed Central  Google Scholar 

Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011;471:467–72.

Article  PubMed  PubMed Central  Google Scholar 

O’Donnell E, Mahindra A, Yee AJ, Nardi V, Birrer N, Horick N, et al. Clinical grade “SNaPshot” genetic mutation profiling in multiple myeloma. EBioMedicine 2015;2:71–3.

Article  PubMed  Google Scholar 

Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol 2015;33:3911–20.

Article  PubMed  Google Scholar 

Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 2008;111:4039–47.

Article  PubMed  PubMed Central  Google Scholar 

Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012;120:1060–6.

Article  PubMed  PubMed Central  Google Scholar 

Xu J, Pfarr N, Endris V, Mai EK, Md Hanafiah NH, Lehners N, et al. Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation. Oncogenesis 2017;6:e337.

Article  PubMed  PubMed Central  Google Scholar 

Frank AJ, Dagogo-Jack I, Dobre IA, Tait S, Schumacher L, Fintelmann FJ, et al. Management of lung cancer in the patient with interstitial lung disease. Oncologist 2023;28:12–22.

Article  PubMed  Google Scholar 

Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging Ras back in the ring. Cancer Cell 2014;25:272–81.

Article  PubMed  Google Scholar 

Renaud S, Seitlinger J, Falcoz PE, Schaeffer M, Voegeli AC, Legrain M, et al. Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery. Br J Cancer 2016;115:346–53.

Article  PubMed  PubMed Central  Google Scholar 

Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973–7.

Article